An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022, taking place in Barcelona, Spain from September 4-6, 2022. The accepted abstracts focus on the efficacy measures in patients requiring lung lavage, safety of inhaled molgramostim for aPAP, and the choice of DLCO as a primary endpoint in aPAP research. Results will be published in the European Respiratory Journal supplement by November 2022.
Positive
Accepted three abstracts for presentation at a major medical congress.
Focus on autoimmune pulmonary alveolar proteinosis (aPAP), an area with no approved treatments, highlighting potential for market opportunity.
Negative
None.
AUSTIN, Texas--(BUSINESS WIRE)--
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022 to be held in-person and virtually, September 4-6, 2022 in Barcelona, Spain.
ERS 2022 Accepted Abstracts:
IMPALA: Efficacy Measures in Patients Who Required Whole Lung Lavage Poster Session: Chronic cough, airway diseases and methods
Date and Time: September 4, 2022, 8:30-9:30 AM CEST
Safety and Tolerability of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Poster Session: Chronic cough, airway diseases and methods
Date and Time: September 4, 2022, 8:30-9:30 AM CEST
IMPALA-2: Choice of DLCO as a Primary Endpoint in aPAP
Poster Session: Chronic cough, airway diseases and methods
Date and Time: September 4, 2022, 8:30-9:30 AM CEST
The full content of these abstracts will be available in the Congress’ online program and will be published in a supplement of the European Respiratory Journal (ERJ) by the end of November 2022. For more details about the ERS International Congress please visit https://www.ersnet.org/congress-and-events/congress/.
About aPAP
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease that belongs to a family of distinct rare lung diseases collectively known as pulmonary alveolar proteinosis (PAP). aPAP represents about 90% of all patients with PAP. While aPAP can affect people of any age, race or sex, onset occurs most frequently in people between the ages of 30 and 40. PAP is characterized by the build-up of surfactant in the alveoli, or air sacs, of the lungs. The surfactant consists of proteins and lipids and is an important physiological substance that lines the inside of the alveoli to prevent the lungs from collapsing. The root cause of aPAP is an autoimmune response against GM-CSF, a naturally occurring protein in the body. Pulmonary macrophages need to be stimulated by GM-CSF to function properly, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering the macrophages unable to perform their tasks, including the clearance of surfactant from the alveoli. In aPAP, the feeling of having trouble breathing is the most common symptom. People with aPAP can also experience chronic cough, fatigue, sputum production, reduced ability to exercise and episodes of fever due to underlying pulmonary infections. There are currently no approved pharmaceutical treatment options for aPAP.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
What abstracts did Savara Inc. present at the ERS International Congress 2022?
Savara Inc. presented three abstracts focusing on efficacy measures in patients requiring lung lavage, safety and tolerability of inhaled molgramostim for aPAP, and DLCO as a primary endpoint in aPAP clinical research.
When is the ERS International Congress taking place?
The ERS International Congress is scheduled for September 4-6, 2022.
Where will Savara's research be published?
The full content of the accepted abstracts will be published in a supplement of the European Respiratory Journal by the end of November 2022.
What is the significance of the abstracts presented by Savara Inc.?
The presentations focus on aPAP, a rare lung disease with no current pharmaceutical treatment options, which may signal potential advancements in therapy and market opportunity.
